INJEX Pharma AG
INJEX Pharma AG: INJEX Pharma AG obtains Chinese SFDA registration for INJEX30 needle free injection system
INJEX Pharma AG / Key word(s): Miscellaneous 16.04.2013 10:13 Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP - a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- Ad hoc Release: INJEX Pharma AG obtains Chinese SFDA registration for INJEX30 needle free injection system China, April 16, 2013 - INJEX Pharma AG is pleased to announce that yesterday its wholly owned subsidiary INJEX Pharma GmbH has successfully registered the INJEX30 needle free injection system with the Chinese State Food and Drug Administration (SFDA), supported by its exclusive distributor Hangzhou Hema Medical Equipment Co. Ltd. The SFDA is responsible for regulating the market access of medical devices in the People's Republic of China. The arduous approval process took more than 1.5 years and has required a detailed documentation. The registration is a significant milestone in the Company's efforts to expand its offerings in key markets. One area of application is the use of insulin for persons with diabetes. According to figures in the recent Diabetes Atlas (5th edition, 2012) published by the International Diabetes Federation, about one fourth of the 371 million people with diabetes live in China. Hangzhou Hema Medical Equipment can immediately start marketing the INJEX30 system. For further information on INJEX Pharma AG and its subsidiaries, please refer to www.injex.com. For further questions please contact our Investor Relations team directly: INJEX Pharma AG Investor Relations Team t: +49 89 24 41 18 - 223 f: +49 89 24 41 18 - 499 ir@injex.com INJEX Pharma AG: INJEX Pharma Aktiengesellschaft and its subsidiaries INJEX Pharma GmbH and INJEX Vertrieb Deutschland GmbH are specialized in the development, manufacturing and marketing in the medical technology segment and in the cosmetics and beauty markets. The Group's core business areas are the needle-free INJEX30 system and the product line SHIREEN in the beauty market. The main markets of the Group are North America, China, India, Russia and Europe. 16.04.2013 DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------------- Language: English Company: INJEX Pharma AG Buckower Damm 114 12349 Berlin Germany Phone: +49 89 24 41 18 - 223 Fax: +49 89 24 41 18 - 499 E-mail: ir@injex.de Internet: www.injex.de ISIN: DE000A0STYL7 WKN: A0STYL Listed: Regulierter Markt in Frankfurt (General Standard) Notierung vorgesehen / designated to be listed End of Announcement DGAP News-Service ---------------------------------------------------------------------------
Latest News
Latest Reports
No Reports found
Upcoming Events
No Events found
Webcasts
No Webcasts found